ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Vaccine Adjuvants Market Research Report 2025
Published Date: 2025-12-26
|
Report Code: QYRE-Auto-16A8759
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Human Vaccine Adjuvants Market Insights and Forecast to 2028
BUY CHAPTERS

Global Human Vaccine Adjuvants Market Research Report 2025

Code: QYRE-Auto-16A8759
Report
2025-12-26
Pages:113
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
CSL Limited
SEPPIC
CRODA
SDA BIO
SPI Pharma
Phibro Animal Health
Vertellus
Iseevax
VARNOTECH

Human Vaccine Adjuvants Market Size

The global market for Human Vaccine Adjuvants was valued at US$ 421 million in the year 2024 and is projected to reach a revised size of US$ 699 million by 2031, growing at a CAGR of 7.5% during the forecast period.

Human Vaccine Adjuvants Market

Human Vaccine Adjuvants Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Human Vaccine Adjuvants competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Human vaccine adjuvants are functional components formulated into vaccines for human use to enhance antigen presentation and to activate or modulate innate and adaptive immune pathways, enabling stronger and longer-lasting protection with lower antigen doses and fewer administrations. Human adjuvants span traditional aluminum salts and emulsion systems to next-generation molecular and nanostructured platforms such as lipid nanoparticles (LNPs) and immune pattern-recognition receptor agonists (e.g., TLR, STING). As recombinant protein, nucleic acid, and cancer vaccine platforms commercialize, adjuvants have evolved from ancillary ingredients into strategic technology assets that determine immunogenicity, safety margins, and manufacturing scalability—becoming a primary differentiator for industry players. In 2024, global Human vaccine adjuvants production reached approximately 2.81 K MT, with an average global market price of around US$ 150 per kg.The average gross profit margin of this product is 35%.
Global public-health strategies and capital markets are re-evaluating long-term immunization resilience, prompting increased investment in domestic vaccine capabilities and tech sovereignty—elevating high-performance adjuvants to strategic commercial assets. Leading vaccine manufacturers highlight investments in immunology platforms in their annual reports, accelerating the commercial pathways of multiple adjuvant technologies including emulsions, LNPs, and immune agonists. Growth in elderly-immunization, combination vaccines, and cancer immunotherapy expands the market for composite and targeted adjuvants with high added value.
Despite clear opportunities, the sector faces regulatory heterogeneity, the need for long-term clinical safety evaluation, and scale-up process challenges. Divergent regional registration standards and evolving regulatory expectations raise compliance costs during R&D and manufacturing. Advanced adjuvant scale-up requires breakthroughs in batch consistency, impurity control, and traceability, while patent and licensing barriers for core technologies increase commercial-entry and partnership negotiation risks for smaller players.
Vaccine developers are shifting from product-centric rivalry to platform-driven differentiation, favoring adjuvant systems that combine compatibility, robust clinical evidence, and manufacturability at scale. Corporate reports emphasize leveraging adjuvants to improve immune durability, reduce dosing burden, and simplify immunization schedules—trends that increase bargaining power for suppliers who can demonstrate platform adaptability and production readiness.
Upstream inputs encompass inorganic salts, synthetic lipids, plant-derived adjuvant precursors, nucleic-acid-grade lipids, and specialized surfactants; material quality and traceability fundamentally determine downstream safety and consistency. Annual reports and investor disclosures from major suppliers stress investment in high-purity, low-endotoxin materials and GMP-capable production, indicating a stratification toward higher-end upstream supply. Suppliers with advanced chemical-synthesis, structural-design, and purification capacity are structurally advantaged for adjuvant manufacture.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human Vaccine Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Vaccine Adjuvants.
The Human Vaccine Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Vaccine Adjuvants market comprehensively. Regional market sizes, concerning products by Type, by Application, by Material System and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Vaccine Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Material System and by regions.

Scope of Human Vaccine Adjuvants Market Report

Report Metric Details
Report Name Human Vaccine Adjuvants Market
Accounted market size in year US$ 421 million
Forecasted market size in 2031 US$ 699 million
CAGR 7.5%
Base Year year
Forecasted years 2026 - 2031
Segment by Type
  • Aluminium Salt Adjuvant
  • Oil Emulsion Adjuvant
  • Others
Segment by Material System
  • Inorganic
  • Organic
Segment by Vaccine Platform
  • Protein/peptide Vaccines
  • Nucleic Acid Vaccines
  • Viral Vector Vaccines
  • Other
Segment by Application
  • Commercial
  • Research
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GSK, CSL Limited, Croda, SEPPIC, Iseevax, VARNOTECH, SDA BIO, SPI Pharma, Phibro Animal Health, Vertellus
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Human Vaccine Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Human Vaccine Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Human Vaccine Adjuvants Market growing?

Ans: The Human Vaccine Adjuvants Market witnessing a CAGR of 7.5% during the forecast period 2026-2031.

What is the Human Vaccine Adjuvants Market size in 2031?

Ans: The Human Vaccine Adjuvants Market size in 2031 will be US$ 699 million.

Who are the main players in the Human Vaccine Adjuvants Market report?

Ans: The main players in the Human Vaccine Adjuvants Market are GSK, CSL Limited, Croda, SEPPIC, Iseevax, VARNOTECH, SDA BIO, SPI Pharma, Phibro Animal Health, Vertellus

What are the Application segmentation covered in the Human Vaccine Adjuvants Market report?

Ans: The Applications covered in the Human Vaccine Adjuvants Market report are Commercial, Research

What are the Type segmentation covered in the Human Vaccine Adjuvants Market report?

Ans: The Types covered in the Human Vaccine Adjuvants Market report are Aluminium Salt Adjuvant, Oil Emulsion Adjuvant, Others

1 Human Vaccine Adjuvants Market Overview
1.1 Product Definition
1.2 Human Vaccine Adjuvants by Type
1.2.1 Global Human Vaccine Adjuvants Market Value Comparison by Type (2024 VS 2031)
1.2.2 Aluminium Salt Adjuvant
1.2.3 Oil Emulsion Adjuvant
1.2.4 Others
1.3 Human Vaccine Adjuvants by Material System
1.3.1 Global Human Vaccine Adjuvants Market Value Comparison by Material System: 2024 VS 2031
1.3.2 Inorganic
1.3.3 Organic
1.4 Human Vaccine Adjuvants by Vaccine Platform
1.4.1 Global Human Vaccine Adjuvants Market Value Comparison by Vaccine Platform: 2024 VS 2031
1.4.2 Protein/peptide Vaccines
1.4.3 Nucleic Acid Vaccines
1.4.4 Viral Vector Vaccines
1.4.5 Other
1.5 Human Vaccine Adjuvants by Application
1.5.1 Global Human Vaccine Adjuvants Market Value by Application (2024 VS 2031)
1.5.2 Commercial
1.5.3 Research
1.6 Global Human Vaccine Adjuvants Market Size Estimates and Forecasts
1.6.1 Global Human Vaccine Adjuvants Revenue 2020-2031
1.6.2 Global Human Vaccine Adjuvants Sales 2020-2031
1.6.3 Global Human Vaccine Adjuvants Market Average Price (2020-2031)
1.7 Assumptions and Limitations
2 Human Vaccine Adjuvants Market Competition by Manufacturers
2.1 Global Human Vaccine Adjuvants Sales Market Share by Manufacturers (2020-2025)
2.2 Global Human Vaccine Adjuvants Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Human Vaccine Adjuvants Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Human Vaccine Adjuvants, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Vaccine Adjuvants, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Vaccine Adjuvants, Product Type & Application
2.7 Global Key Manufacturers of Human Vaccine Adjuvants, Date of Enter into This Industry
2.8 Global Human Vaccine Adjuvants Market Competitive Situation and Trends
2.8.1 Global Human Vaccine Adjuvants Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Human Vaccine Adjuvants Players Market Share by Revenue
2.8.3 Global Human Vaccine Adjuvants Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Vaccine Adjuvants Market Scenario by Region
3.1 Global Human Vaccine Adjuvants Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Human Vaccine Adjuvants Sales by Region: 2020-2031
3.2.1 Global Human Vaccine Adjuvants Sales by Region: 2020-2025
3.2.2 Global Human Vaccine Adjuvants Sales by Region: 2026-2031
3.3 Global Human Vaccine Adjuvants Revenue by Region: 2020-2031
3.3.1 Global Human Vaccine Adjuvants Revenue by Region: 2020-2025
3.3.2 Global Human Vaccine Adjuvants Revenue by Region: 2026-2031
3.4 North America Human Vaccine Adjuvants Market Facts & Figures by Country
3.4.1 North America Human Vaccine Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Human Vaccine Adjuvants Sales by Country (2020-2031)
3.4.3 North America Human Vaccine Adjuvants Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Vaccine Adjuvants Market Facts & Figures by Country
3.5.1 Europe Human Vaccine Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Human Vaccine Adjuvants Sales by Country (2020-2031)
3.5.3 Europe Human Vaccine Adjuvants Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Vaccine Adjuvants Market Facts & Figures by Region
3.6.1 Asia Pacific Human Vaccine Adjuvants Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Human Vaccine Adjuvants Sales by Region (2020-2031)
3.6.3 Asia Pacific Human Vaccine Adjuvants Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Human Vaccine Adjuvants Market Facts & Figures by Country
3.7.1 Latin America Human Vaccine Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Human Vaccine Adjuvants Sales by Country (2020-2031)
3.7.3 Latin America Human Vaccine Adjuvants Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Vaccine Adjuvants Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Vaccine Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Human Vaccine Adjuvants Sales by Country (2020-2031)
3.8.3 Middle East and Africa Human Vaccine Adjuvants Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Vaccine Adjuvants Sales by Type (2020-2031)
4.1.1 Global Human Vaccine Adjuvants Sales by Type (2020-2025)
4.1.2 Global Human Vaccine Adjuvants Sales by Type (2026-2031)
4.1.3 Global Human Vaccine Adjuvants Sales Market Share by Type (2020-2031)
4.2 Global Human Vaccine Adjuvants Revenue by Type (2020-2031)
4.2.1 Global Human Vaccine Adjuvants Revenue by Type (2020-2025)
4.2.2 Global Human Vaccine Adjuvants Revenue by Type (2026-2031)
4.2.3 Global Human Vaccine Adjuvants Revenue Market Share by Type (2020-2031)
4.3 Global Human Vaccine Adjuvants Price by Type (2020-2031)
5 Segment by Application
5.1 Global Human Vaccine Adjuvants Sales by Application (2020-2031)
5.1.1 Global Human Vaccine Adjuvants Sales by Application (2020-2025)
5.1.2 Global Human Vaccine Adjuvants Sales by Application (2026-2031)
5.1.3 Global Human Vaccine Adjuvants Sales Market Share by Application (2020-2031)
5.2 Global Human Vaccine Adjuvants Revenue by Application (2020-2031)
5.2.1 Global Human Vaccine Adjuvants Revenue by Application (2020-2025)
5.2.2 Global Human Vaccine Adjuvants Revenue by Application (2026-2031)
5.2.3 Global Human Vaccine Adjuvants Revenue Market Share by Application (2020-2031)
5.3 Global Human Vaccine Adjuvants Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Human Vaccine Adjuvants Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 CSL Limited
6.2.1 CSL Limited Company Information
6.2.2 CSL Limited Description and Business Overview
6.2.3 CSL Limited Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.2.4 CSL Limited Human Vaccine Adjuvants Product Portfolio
6.2.5 CSL Limited Recent Developments/Updates
6.3 Croda
6.3.1 Croda Company Information
6.3.2 Croda Description and Business Overview
6.3.3 Croda Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Croda Human Vaccine Adjuvants Product Portfolio
6.3.5 Croda Recent Developments/Updates
6.4 SEPPIC
6.4.1 SEPPIC Company Information
6.4.2 SEPPIC Description and Business Overview
6.4.3 SEPPIC Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.4.4 SEPPIC Human Vaccine Adjuvants Product Portfolio
6.4.5 SEPPIC Recent Developments/Updates
6.5 Iseevax
6.5.1 Iseevax Company Information
6.5.2 Iseevax Description and Business Overview
6.5.3 Iseevax Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Iseevax Human Vaccine Adjuvants Product Portfolio
6.5.5 Iseevax Recent Developments/Updates
6.6 VARNOTECH
6.6.1 VARNOTECH Company Information
6.6.2 VARNOTECH Description and Business Overview
6.6.3 VARNOTECH Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.6.4 VARNOTECH Human Vaccine Adjuvants Product Portfolio
6.6.5 VARNOTECH Recent Developments/Updates
6.7 SDA BIO
6.7.1 SDA BIO Company Information
6.7.2 SDA BIO Description and Business Overview
6.7.3 SDA BIO Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.7.4 SDA BIO Human Vaccine Adjuvants Product Portfolio
6.7.5 SDA BIO Recent Developments/Updates
6.8 SPI Pharma
6.8.1 SPI Pharma Company Information
6.8.2 SPI Pharma Description and Business Overview
6.8.3 SPI Pharma Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.8.4 SPI Pharma Human Vaccine Adjuvants Product Portfolio
6.8.5 SPI Pharma Recent Developments/Updates
6.9 Phibro Animal Health
6.9.1 Phibro Animal Health Company Information
6.9.2 Phibro Animal Health Description and Business Overview
6.9.3 Phibro Animal Health Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Phibro Animal Health Human Vaccine Adjuvants Product Portfolio
6.9.5 Phibro Animal Health Recent Developments/Updates
6.10 Vertellus
6.10.1 Vertellus Company Information
6.10.2 Vertellus Description and Business Overview
6.10.3 Vertellus Human Vaccine Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Vertellus Human Vaccine Adjuvants Product Portfolio
6.10.5 Vertellus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Vaccine Adjuvants Industry Chain Analysis
7.2 Human Vaccine Adjuvants Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Vaccine Adjuvants Production Mode & Process Analysis
7.4 Human Vaccine Adjuvants Sales and Marketing
7.4.1 Human Vaccine Adjuvants Sales Channels
7.4.2 Human Vaccine Adjuvants Distributors
7.5 Human Vaccine Adjuvants Customer Analysis
8 Human Vaccine Adjuvants Market Dynamics
8.1 Human Vaccine Adjuvants Industry Trends
8.2 Human Vaccine Adjuvants Market Drivers
8.3 Human Vaccine Adjuvants Market Challenges
8.4 Human Vaccine Adjuvants Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GSK
CSL Limited
SEPPIC
CRODA
SDA BIO
SPI Pharma
Phibro Animal Health
Vertellus
Iseevax
VARNOTECH
List of Tables
 Table 1. Global Human Vaccine Adjuvants Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Human Vaccine Adjuvants Market Value by Material System, (US$ Million) & (2024 VS 2031)
 Table 3. Global Human Vaccine Adjuvants Market Value by Vaccine Platform, (US$ Million) & (2024 VS 2031)
 Table 4. Global Human Vaccine Adjuvants Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 5. Global Human Vaccine Adjuvants Market Competitive Situation by Manufacturers in 2024
 Table 6. Global Human Vaccine Adjuvants Sales (Tons) of Key Manufacturers (2020-2025)
 Table 7. Global Human Vaccine Adjuvants Sales Market Share by Manufacturers (2020-2025)
 Table 8. Global Human Vaccine Adjuvants Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 9. Global Human Vaccine Adjuvants Revenue Share by Manufacturers (2020-2025)
 Table 10. Global Market Human Vaccine Adjuvants Average Price (US$/kg) of Key Manufacturers (2020-2025)
 Table 11. Global Key Players of Human Vaccine Adjuvants, Industry Ranking, 2022 VS 2023 VS 2024
 Table 12. Global Key Manufacturers of Human Vaccine Adjuvants, Manufacturing Sites & Headquarters
 Table 13. Global Key Manufacturers of Human Vaccine Adjuvants, Product Type & Application
 Table 14. Global Key Manufacturers of Human Vaccine Adjuvants, Date of Enter into This Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global Human Vaccine Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Vaccine Adjuvants as of 2024)
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global Human Vaccine Adjuvants Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 19. Global Human Vaccine Adjuvants Sales by Region (2020-2025) & (Tons)
 Table 20. Global Human Vaccine Adjuvants Sales Market Share by Region (2020-2025)
 Table 21. Global Human Vaccine Adjuvants Sales by Region (2026-2031) & (Tons)
 Table 22. Global Human Vaccine Adjuvants Sales Market Share by Region (2026-2031)
 Table 23. Global Human Vaccine Adjuvants Revenue by Region (2020-2025) & (US$ Million)
 Table 24. Global Human Vaccine Adjuvants Revenue Market Share by Region (2020-2025)
 Table 25. Global Human Vaccine Adjuvants Revenue by Region (2026-2031) & (US$ Million)
 Table 26. Global Human Vaccine Adjuvants Revenue Market Share by Region (2026-2031)
 Table 27. North America Human Vaccine Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. North America Human Vaccine Adjuvants Sales by Country (2020-2025) & (Tons)
 Table 29. North America Human Vaccine Adjuvants Sales by Country (2026-2031) & (Tons)
 Table 30. North America Human Vaccine Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 31. North America Human Vaccine Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 32. Europe Human Vaccine Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 33. Europe Human Vaccine Adjuvants Sales by Country (2020-2025) & (Tons)
 Table 34. Europe Human Vaccine Adjuvants Sales by Country (2026-2031) & (Tons)
 Table 35. Europe Human Vaccine Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 36. Europe Human Vaccine Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 37. Asia Pacific Human Vaccine Adjuvants Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 38. Asia Pacific Human Vaccine Adjuvants Sales by Region (2020-2025) & (Tons)
 Table 39. Asia Pacific Human Vaccine Adjuvants Sales by Region (2026-2031) & (Tons)
 Table 40. Asia Pacific Human Vaccine Adjuvants Revenue by Region (2020-2025) & (US$ Million)
 Table 41. Asia Pacific Human Vaccine Adjuvants Revenue by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Human Vaccine Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Latin America Human Vaccine Adjuvants Sales by Country (2020-2025) & (Tons)
 Table 44. Latin America Human Vaccine Adjuvants Sales by Country (2026-2031) & (Tons)
 Table 45. Latin America Human Vaccine Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Human Vaccine Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 47. Middle East and Africa Human Vaccine Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 48. Middle East and Africa Human Vaccine Adjuvants Sales by Country (2020-2025) & (Tons)
 Table 49. Middle East and Africa Human Vaccine Adjuvants Sales by Country (2026-2031) & (Tons)
 Table 50. Middle East and Africa Human Vaccine Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 51. Middle East and Africa Human Vaccine Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 52. Global Human Vaccine Adjuvants Sales (Tons) by Type (2020-2025)
 Table 53. Global Human Vaccine Adjuvants Sales (Tons) by Type (2026-2031)
 Table 54. Global Human Vaccine Adjuvants Sales Market Share by Type (2020-2025)
 Table 55. Global Human Vaccine Adjuvants Sales Market Share by Type (2026-2031)
 Table 56. Global Human Vaccine Adjuvants Revenue (US$ Million) by Type (2020-2025)
 Table 57. Global Human Vaccine Adjuvants Revenue (US$ Million) by Type (2026-2031)
 Table 58. Global Human Vaccine Adjuvants Revenue Market Share by Type (2020-2025)
 Table 59. Global Human Vaccine Adjuvants Revenue Market Share by Type (2026-2031)
 Table 60. Global Human Vaccine Adjuvants Price (US$/kg) by Type (2020-2025)
 Table 61. Global Human Vaccine Adjuvants Price (US$/kg) by Type (2026-2031)
 Table 62. Global Human Vaccine Adjuvants Sales (Tons) by Application (2020-2025)
 Table 63. Global Human Vaccine Adjuvants Sales (Tons) by Application (2026-2031)
 Table 64. Global Human Vaccine Adjuvants Sales Market Share by Application (2020-2025)
 Table 65. Global Human Vaccine Adjuvants Sales Market Share by Application (2026-2031)
 Table 66. Global Human Vaccine Adjuvants Revenue (US$ Million) by Application (2020-2025)
 Table 67. Global Human Vaccine Adjuvants Revenue (US$ Million) by Application (2026-2031)
 Table 68. Global Human Vaccine Adjuvants Revenue Market Share by Application (2020-2025)
 Table 69. Global Human Vaccine Adjuvants Revenue Market Share by Application (2026-2031)
 Table 70. Global Human Vaccine Adjuvants Price (US$/kg) by Application (2020-2025)
 Table 71. Global Human Vaccine Adjuvants Price (US$/kg) by Application (2026-2031)
 Table 72. GSK Company Information
 Table 73. GSK Description and Business Overview
 Table 74. GSK Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 75. GSK Human Vaccine Adjuvants Product
 Table 76. GSK Recent Developments/Updates
 Table 77. CSL Limited Company Information
 Table 78. CSL Limited Description and Business Overview
 Table 79. CSL Limited Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 80. CSL Limited Human Vaccine Adjuvants Product
 Table 81. CSL Limited Recent Developments/Updates
 Table 82. Croda Company Information
 Table 83. Croda Description and Business Overview
 Table 84. Croda Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 85. Croda Human Vaccine Adjuvants Product
 Table 86. Croda Recent Developments/Updates
 Table 87. SEPPIC Company Information
 Table 88. SEPPIC Description and Business Overview
 Table 89. SEPPIC Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 90. SEPPIC Human Vaccine Adjuvants Product
 Table 91. SEPPIC Recent Developments/Updates
 Table 92. Iseevax Company Information
 Table 93. Iseevax Description and Business Overview
 Table 94. Iseevax Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 95. Iseevax Human Vaccine Adjuvants Product
 Table 96. Iseevax Recent Developments/Updates
 Table 97. VARNOTECH Company Information
 Table 98. VARNOTECH Description and Business Overview
 Table 99. VARNOTECH Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 100. VARNOTECH Human Vaccine Adjuvants Product
 Table 101. VARNOTECH Recent Developments/Updates
 Table 102. SDA BIO Company Information
 Table 103. SDA BIO Description and Business Overview
 Table 104. SDA BIO Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 105. SDA BIO Human Vaccine Adjuvants Product
 Table 106. SDA BIO Recent Developments/Updates
 Table 107. SPI Pharma Company Information
 Table 108. SPI Pharma Description and Business Overview
 Table 109. SPI Pharma Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 110. SPI Pharma Human Vaccine Adjuvants Product
 Table 111. SPI Pharma Recent Developments/Updates
 Table 112. Phibro Animal Health Company Information
 Table 113. Phibro Animal Health Description and Business Overview
 Table 114. Phibro Animal Health Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 115. Phibro Animal Health Human Vaccine Adjuvants Product
 Table 116. Phibro Animal Health Recent Developments/Updates
 Table 117. Vertellus Company Information
 Table 118. Vertellus Description and Business Overview
 Table 119. Vertellus Human Vaccine Adjuvants Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 120. Vertellus Human Vaccine Adjuvants Product
 Table 121. Vertellus Recent Developments/Updates
 Table 122. Key Raw Materials Lists
 Table 123. Raw Materials Key Suppliers Lists
 Table 124. Human Vaccine Adjuvants Distributors List
 Table 125. Human Vaccine Adjuvants Customers List
 Table 126. Human Vaccine Adjuvants Market Trends
 Table 127. Human Vaccine Adjuvants Market Drivers
 Table 128. Human Vaccine Adjuvants Market Challenges
 Table 129. Human Vaccine Adjuvants Market Restraints
 Table 130. Research Programs/Design for This Report
 Table 131. Key Data Information from Secondary Sources
 Table 132. Key Data Information from Primary Sources
 Table 133. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Vaccine Adjuvants
 Figure 2. Global Human Vaccine Adjuvants Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Human Vaccine Adjuvants Market Share by Type: 2024 & 2031
 Figure 4. Aluminium Salt Adjuvant Product Picture
 Figure 5. Oil Emulsion Adjuvant Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Human Vaccine Adjuvants Market Value by Material System, (US$ Million) & (2020-2031)
 Figure 8. Global Human Vaccine Adjuvants Market Share by Material System: 2024 VS 2031
 Figure 9. Inorganic Product Picture
 Figure 10. Organic Product Picture
 Figure 11. Global Human Vaccine Adjuvants Market Value by Vaccine Platform, (US$ Million) & (2020-2031)
 Figure 12. Global Human Vaccine Adjuvants Market Share by Vaccine Platform: 2024 VS 2031
 Figure 13. Protein/peptide Vaccines Product Picture
 Figure 14. Nucleic Acid Vaccines Product Picture
 Figure 15. Viral Vector Vaccines Product Picture
 Figure 16. Other Product Picture
 Figure 17. Global Human Vaccine Adjuvants Market Value by Application (2020-2031) & (US$ Million)
 Figure 18. Global Human Vaccine Adjuvants Market Share by Application: 2024 & 2031
 Figure 19. Commercial
 Figure 20. Research
 Figure 21. Global Human Vaccine Adjuvants Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 22. Global Human Vaccine Adjuvants Market Size (2020-2031) & (US$ Million)
 Figure 23. Global Human Vaccine Adjuvants Sales (2020-2031) & (Tons)
 Figure 24. Global Human Vaccine Adjuvants Average Price (US$/kg) & (2020-2031)
 Figure 25. Human Vaccine Adjuvants Report Years Considered
 Figure 26. Human Vaccine Adjuvants Sales Share by Manufacturers in 2024
 Figure 27. Global Human Vaccine Adjuvants Revenue Share by Manufacturers in 2024
 Figure 28. Global 5 and 10 Largest Human Vaccine Adjuvants Players: Market Share by Revenue in Human Vaccine Adjuvants in 2024
 Figure 29. Human Vaccine Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 30. Global Human Vaccine Adjuvants Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 31. North America Human Vaccine Adjuvants Sales Market Share by Country (2020-2031)
 Figure 32. North America Human Vaccine Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 33. United States Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Canada Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Europe Human Vaccine Adjuvants Sales Market Share by Country (2020-2031)
 Figure 36. Europe Human Vaccine Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 37. Germany Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. France Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. U.K. Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Italy Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Russia Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Asia Pacific Human Vaccine Adjuvants Sales Market Share by Region (2020-2031)
 Figure 43. Asia Pacific Human Vaccine Adjuvants Revenue Market Share by Region (2020-2031)
 Figure 44. China Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Japan Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. South Korea Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. India Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Australia Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. China Taiwan Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Indonesia Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Thailand Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Malaysia Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Latin America Human Vaccine Adjuvants Sales Market Share by Country (2020-2031)
 Figure 54. Latin America Human Vaccine Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 55. Mexico Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Brazil Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Argentina Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Middle East and Africa Human Vaccine Adjuvants Sales Market Share by Country (2020-2031)
 Figure 59. Middle East and Africa Human Vaccine Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 60. Turkey Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 61. Saudi Arabia Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 62. UAE Human Vaccine Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 63. Global Sales Market Share of Human Vaccine Adjuvants by Type (2020-2031)
 Figure 64. Global Revenue Market Share of Human Vaccine Adjuvants by Type (2020-2031)
 Figure 65. Global Human Vaccine Adjuvants Price (US$/kg) by Type (2020-2031)
 Figure 66. Global Sales Market Share of Human Vaccine Adjuvants by Application (2020-2031)
 Figure 67. Global Revenue Market Share of Human Vaccine Adjuvants by Application (2020-2031)
 Figure 68. Global Human Vaccine Adjuvants Price (US$/kg) by Application (2020-2031)
 Figure 69. Human Vaccine Adjuvants Value Chain
 Figure 70. Channels of Distribution (Direct Vs Distribution)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Immune Adjuvant Market Research Report 2024
Global Adjuvants in Agriculture Market Research Report 2024
Global Biological Vaccines Adjuvants Market Research Report 2025
Global Human Immunoassay Market Research Report 2025
Global Adult Vaccines Market Research Report 2024
Global Fungicide Adjuvants Market Research Report 2025
Global Seasonal Vaccines Market Research Report 2024
Global Vaccine Particulate Adjuvants Market Research Report 2025
Global HIV Vaccine Market Research Report 2025
Global Adjuvant Therapy Market Research Report 2024
Global Oral Vaccine Adjuvants Market Research Report 2025
Global Agricultural Utility Adjuvants Market Research Report 2025
Global Human Immunoglobulin Market Research Report 2024
Global Vaccines for the Elderly Market Research Report 2024
Global Utility Agricultural Adjuvants Market Research Report 2025
Global Adult and Pediatric Vaccines Market Research Report 2024
Global Human Histaglobulin Market Research Report 2024
Global Food Allergy Vaccine Market Research Report 2024
Global Agriculture Fungicide Adjuvants Market Research Report 2025
Global Agricultural Activator Adjuvants Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions